Stockreport

Mineralys Therapeutics Inc (MLYS) Q3 2025 Earnings Call Highlights: Strong Financial Position ... [Yahoo! Finance]

Mineralys Therapeutics, Inc.  (MLYS) 
PDF R&D Expenses: $31.5 million for Q3 2025, down from $54 million for Q3 2024. G&A Expenses: $9.7 million for Q3 2025, up from $6.1 million for Q3 2024. Total Other In [Read more]